The ability of epidermal growth factor (EGF) to affect adipose tissue development in vivo was investigated. The subcutaneous administration of EGF to newborn NBR rats for 10 days resulted in decreased body weight and fat pad weight that occurred in a dose-dependent fashion. At a dose of 1 ,Ig/g of body weight, injected EGF resulted in a 50% decrease of fat pad weight. Although kidney weight was also diminished, the weight of other organs such as liver and intestine remained unchanged or even slightly increased, suggesting that the effect of EGF on fat pad development was not due to a generalized inhibitory action of EGF on the development of the neonate rats. The number of adipocyte precursors in inguinal fat pads of EGF-treated animals was higher than in control animals (1.3-fold for 0.3 jtg/g of body weight of EGF and 1.8-fold for 1.0 jtg/g of body weight), whereas the number of mature adipocytes and the amount of triglyceride accumulated per fat pad were concomitantly lower. Adipocyte precursors isolated from EGF-treated animals displayed a reduced differentiation ability in culture and a higher sensitivity to the inhibitory effect of EGF than did cells isolated from control animals. These experiments demonstrate that EGF can retard adipose tissue development in vivo and suggest that EGF plays an important physiological role in the control of adipocyte differentiation.
ABSTRACT
The ability of epidermal growth factor (EGF) to affect adipose tissue development in vivo was investigated. The subcutaneous administration of EGF to newborn NBR rats for 10 days resulted in decreased body weight and fat pad weight that occurred in a dose-dependent fashion. At a dose of 1 ,Ig/g of body weight, injected EGF resulted in a 50% decrease of fat pad weight. Although kidney weight was also diminished, the weight of other organs such as liver and intestine remained unchanged or even slightly increased, suggesting that the effect of EGF on fat pad development was not due to a generalized inhibitory action of EGF on the development of the neonate rats. The number of adipocyte precursors in inguinal fat pads of EGF-treated animals was higher than in control animals (1.3-fold for 0.3 jtg/g of body weight of EGF and 1.8-fold for 1.0 jtg/g of body weight), whereas the number of mature adipocytes and the amount of triglyceride accumulated per fat pad were concomitantly lower. Adipocyte precursors isolated from EGF-treated animals displayed a reduced differentiation ability in culture and a higher sensitivity to the inhibitory effect of EGF than did cells isolated from control animals. These experiments demonstrate that EGF can retard adipose tissue development in vivo and suggest that EGF plays an important physiological role in the control of adipocyte differentiation.
The identification of the hormones controlling adipocyte proliferation and differentiation is a very important question to investigate to understand normal adipose tissue development and to possibly define ways to control an abnormal state of adipose tissue development such as obesity. The establishment of several adipogenic cell lines able to undergo differentiation in vitro into fully mature adipocytes has provided model systems to investigate the process of differentiation at the cellular and molecular levels (1) (2) (3) . Using these cell lines, several hormones and growth factors have been shown to have adipogenic (3) (4) (5) or antiadipogenic activities (6) (7) (8) (9) . To determine whether a factor identified with an adipogenic cell line is involved in the physiological regulation of adipose tissue development, one can investigate if adipocyte precursors in primary culture are responsive to this factor and, ultimately, if this factor can efficiently and specifically modulate adipose tissue development in vivo. In the context of these studies, we have been interested in investigating the role of epidermal growth factor (EGF) on adipose differentiation. Recently, we have shown that EGF was a potent inhibitor of the differentiation of primary culture adipocyte precursors isolated from inguinal fat pad of newborn rats (10) .
EGF is a polypeptide with a molecular mass of 6 kDa that is found in high concentrations in the submaxillary glands and at lower levels in the circulation (11, 12) . It has been shown that EGF affects the proliferation and the maintenance of functional properties of various mammalian cells in vitro (13, 14) . Concomitantly, animal experiments involving EGF injection, anti-EGF antiserum injection, or sialoadenectomy have shown that EGF played a physiological role in the maintenance of several tissue functions in vivo (15) (16) (17) (18) (19) (20) (21) (22) . Therefore, by performing in vivo experiments, it is possible to investigate whether the effect of EGF on a specific tissue function demonstrated in vitro is similar in vivo. Such a demonstration is useful to determine the physiological role of EGF during development. In the present paper, animal experiments were performed to determine whether EGF, which is a potent adipose-differentiation inhibitor in vitro, could also affect neonatal adipose tissue development in vivo.
MATERIALS AND METHODS
Animals. New Zealand Brown (NBR) rats (Trudeau Institute, Saranac Lake, NY) were mated in our animal facilities. One day after delivery, litter size was adjusted from six pups to eight pups per female according to the size and age of the females. No more than eight pups per female were used. Mothers were fed ad libitum a regular laboratory diet and were allowed free access to water. Animals were housed in an air-, temperature-, and light-controlled (12 hr of light between 0600 and 1800) room.
Treatment. Mouse receptor grade EGF (Biomedical Technologies, Stoughton, MA) was used in all of our experiments. It was shown to have full biological activity as assessed by binding activity in a radioreceptor assay and by its ability to inhibit adipose differentiation in the primary culture of adipocyte precursors (10) . Twenty-four hours after birth, animals were injected subcutaneously every day for 10 days with EGF dissolved in physiological saline at doses varying between 0.1 ;Lg/g of body weight and 1.0 ,.g/g of body weight.
Animals were weighed prior to being injected. Control animals were also weighed and received the same volume of physiological saline.
Primary Culture of Adipocyte Precursors of Inguinal Fat Pads. Inguinal fat pads are well developed postnatally in 10-day-old animals and they can be easily dissected. Inguinal fat pads were excised, weighed, and pooled. They were digested with collagenase by the method of Bjorntorp et al. (23) , and duplicate aliquots were kept for measuring triglyceride content of fat pads as described below. The conditions of digestion were such that minimum breakage of adipocytes occurred during the incubation time (23) . After digestion, the cell suspension was filtered through a 253-gm nylon mesh filter. Adipocytes were easily recovered by two successive flotations of the cell suspension. The infranatant containing the adipocyte precursors was removed with a plastic pipet and further filtered through an 80-,um nylon mesh. The Abbreviations: EGF, epidermal growth factor; G3PDH, glycerol-3-phosphate dehydrogenase. *To whom reprint requests should be addressed.
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adipocytes remained in the tube after removal of the infranatant. They were gently resuspended in culture medium and counted with a hemocytometer. The filtrate containing the adipocyte precursors was centrifuged twice at 200 x g for 5 min. Adipocyte precursor pellets were resuspended in 4F medium. The cells were subsequently counted in a hemocytometer and inoculated in 35-mm dishes in 4F medium as described (24) to examine their ability to differentiate in culture and to measure their responsiveness to EGF. The defined medium called 4F medium consists of 1:1 (vol/vol) Dulbecco's modified Eagle's (DME) medium and Ham's F-12 medium (DME-F-12 medium) containing 15 mM Hepes (pH 7.4), 1.2 mg of sodium bicarbonate per ml, 50 ,ug of gentamicin per ml, and supplemented with fibronectin (2.5 pug/ml), insulin (10 Ag/ml), transferrin (10 ,ug/ml), and fibroblast growth factor (10 ng/ml). The medium was originally developed to support the differentiation of the adipogenic cell line 1246 (25) . When cultivated in these conditions, optimal differentiation of adipocyte precursors in primary culture is achieved within 8 days of culture (24) . Measurement weight, the weight of inguinal fat pad was 50% lower than in control animals ( Fig. 1 Right) . Although some decrease in weight was also observed for kidney, the weight of liver was unchanged, whereas the weight of intestine was increased by the EGF treatment (data not shown), indicating that the effect on fat pad was not due to a general inhibitory action of EGF on the development of newborn rats. The difference of weight seen for inguinal fat pads was also accompanied by a difference of the size and morphology of the fat pads as shown by the photograph in Fig. 2 . After being excised, inguinal fat pads were digested with collagenase to separate adipocyte precursors and mature adipocytes (23) . The number of adipocyte precursors from duplicate samples was counted with a hemocytometer. It was found that the number of adipocyte precursors per fat pad was higher in inguinal fat pads from EGF-treated animals than in those from control rats (Fig. 3 Left). In EGF-treated animals (1 Ag/g of body weight), the number of adipocyte precursors was 1.8-fold higher than found in control animals-. As a marker for the extent of differentiation that took place in the fat pads in vivo, the triglyceride content of fat pads from control and EGF-treated animals was determined. The amount of triglyceride accumulated per fat pad was significantly lower in EGF-injected animals (Fig. 3 Right). It was 80% lower for fat pads isolated from animals treated with 1 ,.g of EGF per g of body weight (Fig. 3 differentiated and moved into the pool of triglyceride-laden adipocytes during the duration of the in vivo experiment.
Comparison of Differentiation Ability of Isolated Adipocyte Precursors. It has been shown (24) that adipocyte precursors freshly isolated from inguinal fat pads of 48-hr-old rats can proliferate and differentiate in defined medium called 4F medium as described. Adipocyte precursors isolated from inguinal fat pads of control and EGF-treated rats were cultivated in 4F medium to determine if their differentiation ability in culture had been affected by the EGF treatment in vivo. To monitor proliferation and differentiation, they were harvested on day 8, a time when the differentiation of cells has reached an optimal level. Differentiation was followed by measuring glycerol-3-phosphate dehydrogenase (G3PDH) specific activity. The cells isolated from fat pads ofboth types of animals could undergo differentiation as shown by the high level of G3PDH specific activity and by the presence of triglycerides accumulated in the cells. However, the level of G3PDH specific activity was 60%o lower in cells isolated from animals injected with 1 ,ug of EGF per g of body weight. The calculation of G3PDH specific activity from five separate experiments indicated that G3PDH specific activity was 812 ± 107 milliunits/mg of protein in control animals and 337 ± 53 milliunits/mg of protein in animals treated with EGF (1 ,ug/g of body weight). The difference in G3PDH specific activities observed was correlated with the fact that cells isolated from EGF-treated animals differentiated at a lower frequency than cells isolated from control animals. The number of cells having accumulated triglycerides (black arrow in Fig. 4 ) was higher in cultures prepared from fat pads from control animals as compared with cultures prepared from EGF-treated animals. In contrast, undifferentiated, fibroblast-like cells (white arrow in Fig. 4 ) appeared at higher frequency in the cultures prepared from EGF-treated animals than in the control cultures. Analysis of all experiments performed show that the differentiation ability of precursors isolated from fat pads of EGF-treated animals was 30-60% lower than with controls according to the dose of EGF injected. No increase in G3PDH specific activity or frequency of differentiation was observed when the cells isolated from fat pads of EGF-treated animals were maintained in culture for a longer time (up to 15 days), indicating that the lower differentiation ability observed for the cells isolated from EGF-treated animals was not due to a delayed rate of differentiation in culture. The same difference between EGFtreated and control animals was observed by measuring other markers of differentiation such as triglyceride accumulation and mRNA expression for G3PDH and for mouse adipocyte binding protein aP2 (data not shown).
EGF Effect on Adipocyte Precursor Differentiation and Proliferation. We have shown (10) that the differentiation of adipocyte precursors cultivated in 4F medium was inhibited by the addition of EGF to the defined medium in a dosedependent fashion. We examined here whether the adipocyte precursors isolated from EGF-treated animals displayed the same responsiveness to the differentiation-inhibiting action of EGF in culture as adipocyte precursors from control animals. For this purpose, adipocyte precursors isolated from inguinal fat pads of control animals or EGF-injected animals (1 ,g/g of body weight) were cultivated in 4F medium alone or in the presence of increasing concentrations of EGF. Adipocyte precursors isolated from EGF-treated animals displayed in culture a higher sensitivity to the differentiation-inhibitory action of EGF than did cells isolated from control animals as followed by measuring G3PDH-specific activity (Fig. 5 Left) . ED50 was 0.5 ng/ml for cells isolated from EGF-treated animals and 0.9 ng/ml for control cells. EGF added to the 4F medium stimulated in vitro proliferation of adipocyte precursors from control and EGFtreated animals (Fig. 5 Right). The difference of sensitivity to the proliferation-stimulating action of EGF between cells isolated from control and EGF-treated animals was not as pronounced as the one observed for inhibition of differentiation (Fig. 5 Left) . Moreover, when comparing EGF effect on differentiation and proliferation of adipocyte precursors from control and EGF-treated animals, concentrations of EGF that inhibited differentiation by 50% had only a moderate effect (cells from control animals) or no effect (cells from EGF-treated animals) on cell proliferation. Stimulation of proliferation was observed at concentrations higher than 1 ng/ml for cells isolated from both control and EGF-treated animals. These results suggest that the EGF effect on differ- entiation might not be directly related to its effect on proliferation. The decreased ability to differentiate and the increased sensitivity to EGF observed for adipocyte precursors isolated for EGF-treated animals were not due to the fact that receptors of adipocyte precursors isolated from EGF-treated animals were already occupied by EGF at the time of isolation and inoculation. The 125I-labeled EGF specific binding study performed on adipocyte precursors from both types of animals showed that specific binding was identical for precursors from EGF-treated or control animals with or without acid wash (4 pg of EGF bound per 105 cells).
Since the experiments described here are whole-animal experiments, one question is whether the inhibition of adipose tissue development caused by EGF injection is due to a direct action of EGF on adipose tissue or whether EGF is acting indirectly via another growth factor or hormone. Several observations would point to direct action of EGF: EGF inhibits the differentiation of primary culture of adipocyte precursors freshly isolated from inguinal fat pads (10); adipocyte precursors have specific EGF receptors on their cell surface (10); during the whole-animal experiments, 125I-labeled EGF injected subcutaneously to newborn rats specifically bound to several organs including inguinal fat pads (data not shown). Skin, which is known to be a target of EGF action in vivo (30), also showed a high level of 1251-labeled EGF binding.
In these studies, EGF was administered subcutaneously to the newborn rats because oftheir small size and to ensure that all of the administered doses are retained. It is not known what level of EGF is achieved by daily injection of EGF at doses between 0.1 and 1 ,ug/g of body weight. However, it is interesting to note that a significant delay of adipose tissue development is already observed at EGF concentration as low as 0.3 pug/g of body weight and that the effect of EGF on adipose tissue development is not due to a general inhibitory effect on development of the newborn rats. These data would suggest that adipose tissue is a target for EGF action in vivo. Preliminary experiments carried out in our laboratory indicated that a 10-day administration of EGF in neonate rats had a prolonged effect on the animals as they remained leaner than the control ones even at 6 weeks of age. More detailed experiments are required to explore the long-term effect of EGF on adipose tissue development.
The results presented in this paper indicate that EGF may be a physiological regulator of adipose tissue development in vivo. Additional support for this conclusion comes from the reports in the literature that obese rodents have either impaired EGF levels (31) or decreased EGF receptor levels (32) . Our own study indicates that Ob/Ob mice have an 80% decrease in the level of EGF in the plasma and in the submaxillary gland when compared with normal littermates (G.S., unpublished data). In the light of this evidence and the present data, it is possible to assume that EGF plays an important role in adipose tissue development and that abnormalities in the level of EGF or its receptor could account for abnormal adipose tissue development.
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